Cancer Cell

Article	Citations
Accelerated approvals: Early-phase success or premature authorization?	1853
Hand in hand to successful immunotherapy: CD8+ T cells and M1-like macrophages swap the baton	547
Diet-microbiome interactions in cancer	539
KIT as a therapeutic target in neuroendocrine prostate cancer	511
TAMing immunity through an unexpected source	389
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer	379
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer	368
Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas	337
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients	311
Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer	308
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition	305
Spatial profiling technologies illuminate the tumor microenvironment	293
Characterization of the generic mutant p53-rescue compounds in a broad range of assays	291
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations	285
EGFR-activated myofibroblasts promote metastasis of pancreatic cancer	284
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling	273
Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron	263
Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer	258
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma	253
T cell dynamism and immune-related adverse events	249
Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target	247
B cell heterogeneity in cancer comes of age	236
Bacteria in metastatic sites: Unveiling hidden players in cancer progression	235
The aging lung microenvironment awakens melanoma metastases	232
Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer	229

Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity	229
T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation	228
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer	228
Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses	224
A holistic view of cancer	223
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer	222
Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion	216
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors	216
High endothelial venules in cancer: Regulation, function, and therapeutic implication	216
Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin	207
Cancer vaccines	200
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments	199
Challenges in neoantigen-directed therapeutics	197
Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer	196
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer	194
Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer	193
Tumor organoid-originated biomarkers predict immune response to PD-1 blockade	193
Gut microbes promote chemoradiotherapy resistance via metabolic cross-feeding	192
Tumor-directed dysregulation of erythroid progenitors drives immunosuppressive myeloid cells	191
Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation	191
The one-two punch: TIM-3 blockade targets immune and tumor cells to knock out pediatric brain tumors	188
Immunosensitivity cuts across mismatch repair status in colorectal cancer	187
Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?	185
A genetic portrait of metastatic seeds in lung adenocarcinoma	183
Revisiting TNM staging for EBV-related nasopharyngeal carcinoma	179
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts	178
Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population	178
Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation	177
Challenges and opportunities for modeling aging and cancer	176
Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma	173
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy	172
Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification	163
Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression	163
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy	161
Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma	154
Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma	153
Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer	151
Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients	150
Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics	150
Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity	150
Hypoxia inducible factor-1α drives cancer resistance to cuproptosis	149
Dissecting bulk transcriptomes of diffuse large B cell lymphoma	149
Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade	148
ILC3 plasticity in microbiome-mediated tumor progression and immunotherapy	145
Single-cell multi-stage spatial evolutional map of esophageal carcinogenesis	139
Response-based molecular subtyping—emergence of the third generation of breast cancer subtypes	138
Hepatobiliary tumor organoids for personalized medicine: a multicenter view on establishment, limitations, and future directions	138
Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells	137
Recognition of observer effect is required for rigor and reproducibility of preclinical animal studies	137
A path to translation: How 3D patient tumor avatars enable next generation precision oncology	136

The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma	135
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD	134
Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1	134
Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma	134
Tumor-infiltrating lymphocytes: A new hope	133
Midkine as a driver of age-related changes and increase in mammary tumorigenesis	130
Integrated proteogenomic characterization of glioblastoma evolution	129
Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers	129
Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment	127
Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring	126
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells	125
Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study	120
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness	120
Immune determinants of the pre-metastatic niche	120
Taxanes directly induce T cell cytotoxic extracellular vesicles to eradicate tumor cells	118
Multiplex computational pathology for treatment response prediction	117
Tumors on different wavelengths	117
Firing up neutrophil anti-tumor immunity with cocktails	116
GDF15 research from bench to bedside	116
A circular RNA in neuroendocrine carcinomas	116
Immunosequencing identifies signatures of T cell responses for early detection of nasopharyngeal carcinoma	115
JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma	115
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma	114
Precise patient stratification in esophageal cancer: Biomarkers for immunochemotherapy	111
New horizons at the interface of artificial intelligence and translational cancer research	109
T cell immune deficiency rather than chromosome instability predisposes patients with short telomere syndromes to squamous cancers	109
Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma	109
The winner takes it all: Competition drives clonal selection in gliomagenesis	107
Distinct spatiotemporal dynamics of CD8+ T cell-derived cytokines in the tumor microenvironment	106
Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer	105
Proteogenomic data and resources for pan-cancer analysis	105
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma	104
Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance	103
The promise and peril of KRAS G12C inhibitors	102
Integrated single cell analysis reveals co-evolution of malignant B cells and tumor micro-environment in transformed follicular lymphoma	102
Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial	102
An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma	101
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia	101
Spatial transcriptomics reveals tryptophan metabolism restricting maturation of intratumoral tertiary lymphoid structures	101
Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models	100
Lactobacillus reuteri—an old acquaintance takes on a new task in colorectal tumor surveillance	99
Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer	98
Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma	97
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer	97
GD2-CAR T cells in patients with osteosarcoma and neuroblastoma—it’s not only the T cells that matter	96
Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer	95
Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer	94
Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers	93
CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4	93
Tumor heterogeneity	93
From intestinal metaplasia to gastric cancer: Witnessing the rise of evil over time and space	93
PD-1 blockade is a promising therapeutic addition to neoadjuvant chemoradiation in locally advanced rectal cancer	92
Squamous cell cancers of the aero-upper digestive tract: A unified perspective on biology, genetics, and therapy	91
Plasma cell and cancer stem cell crosstalk in glioblastoma	91
Stromal lipid species dictate melanoma metastasis and tropism	91
Horizontal mitochondrial transfer in cancer biology: Potential clinical relevance	89
Seed or soil: Tracing the immune subsets in metastatic tumors	89
Stromal barriers to the abscopal effect	89
High-frequency temperature monitoring for early detection of febrile adverse events in patients with cancer	88
Getting a handle on KRAS inhibitor resistance with hapten-mediated anti-tumor immunity	88
Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers	88
Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis	86
Bacteria and fungi: The counteracting modulators of immune responses to radiation therapy in cancer	86
Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy	85
Glioblastoma induces the recruitment and differentiation of dendritic-like “hybrid” neutrophils from skull bone marrow	85
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells	84
Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient	83
High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer	83
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity	83
Tumor microbiome links cellular programs and immunity in pancreatic cancer	83
Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers	83
Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer	82
Architecture sets the path: Breast cancer subtypes differently shape the early brain metastatic niche	82
Vascular characterization reveals immunomodulatory targets for brain metastases	81
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer	81
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative	79
When immunotherapy meets surgery in non-small cell lung cancer	79
Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC	78
Identification of specific PP2A complexes involved in human cell transformation	78
Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: A multicenter phase 2 PLATINUM trial	76

Infiltrating plasma cells maintain glioblastoma stem cells through IgG-Tumor binding	76
Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice	73
When essential metal elements become culprits—Cuproptosis in focus	73
Genomic mapping of metastatic organotropism in lung adenocarcinoma	72
Revealing de novo pyrimidine synthesis as a key vulnerability in brain tumors	70
Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition	70
Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer	70
A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma	69
A first-in-class EGFR-directed KRAS G12V selective inhibitor	68
Overcoming melanoma therapy resistance with RAF-MEK and FAK inhibition	67
Spatiotemporal genomic profiling of intestinal metaplasia reveals clonal dynamics of gastric cancer progression	67
Sex and cancer immunotherapy: Current understanding and challenges	67
A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression	66
The liver as a cytokine factory working on mRNA blueprints for cancer immunotherapy	65
Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer	65
IL-6 blockade in cancer patients treated with immune checkpoint blockade: A win-win strategy	63
Bridging the gap: The future of cancer research and clinical oncology in Cancer Cell	63
Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma	63
Understanding and reversing mammary tumor-driven reprogramming of myelopoiesis to reduce metastatic spread	63
Mutations in IFN-γ signaling genes sensitize tumors to immune checkpoint blockade	63
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma	62
Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance	62
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma	61
Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity	61
Immune phenotypic linkage between colorectal cancer and liver metastasis	61
Neutrophil-activating therapy for the treatment of cancer	60
Carnobacterium maltaromaticum boosts intestinal vitamin D production to suppress colorectal cancer in female mice	60
T cell engagers in solid tumors kick the door down	60
Metabolic regulation of Cathepsin B in tumor macrophages drives their pro-metastatic function	59
Insights into the co-evolution of epithelial cells and fibroblasts in the esophageal tumor microenvironment	59
Cooperative CAR targeting to selectively eliminate AML and minimize escape	59
IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment	58
Senescent alveolar macrophages promote early-stage lung tumorigenesis	58
A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis	57
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts	57
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity	57
Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis	56
Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma	56
A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers	55
Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer	55
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells	54
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)	53
Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer	53
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory	53
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy	52
COVID-19 provides an opportunity to transform cancer research	52
Integrating priorities at the intersection of cancer and neuroscience	52
Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy	51
The importance of ancestry to understanding tumor mutation burden in cancer	51
Probing cancer with small-molecule tools—Progress and challenges	51
Leading medulloblastoma to a differentiation end	51